Top

Annals of Surgical Oncology

Published in:

Open Access 01-02-2011 | Endocrine Tumors

Incidental Thyroid Carcinoma by FDG-PET/CT: A Study of Clinicopathological Characteristics

Authors: T. T. Law, MBBS, MRCS, Brian Hung-Hin Lang, MS, FRACS

Published in: Annals of Surgical Oncology | Issue 2/2011

Abstract

Background

The rising incidence of incidental thyroid carcinoma (ITC) detected during fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scanning poses a challenge to clinicians. The present study aims to critically evaluate the clinicopathological characteristics of ITC detected by FDG-PET/CT.

Methods

Among the 557 patients managed at our institution, 40 (7.2%) patients were identified as having ITC. Of these, 22 patients had their tumor detected by FDG-PET/CT (PET group) and 11 by ultrasonography (USG group). Additional bedside ultrasonography ± fine-needle aspiration (FNA) was done in all patients at their clinic visit. The clinicopathological characteristics were compared between the PET and USG groups.

Results

The PET group had significantly more patients with history of nonthyroidal malignancy (P < 0.001). Papillary carcinoma was the most common histological type in both groups. Despite having similar histological and prognostic features including tumor size, tumor multifocality, capsular invasion, extrathyroidal extension, and lymph node metastases, tumor bilaterality (or presence of contralateral tumor focus) was significantly more frequent in the PET than the USG group (P = 0.04). The tumors were also more advanced by the tumor–node–metastasis (TNM) staging system in the PET group (P = 0.021). None of the contralateral tumor foci were evident preoperatively. One patient in the USG group developed metastatic thyroid carcinoma in neck lymph nodes 28 months after thyroid resection.

Conclusion

ITC by FDG-PET/CT had higher incidence of tumor bilaterality than those detected by ultrasonography. Total thyroidectomy should be considered for ITC detected by FDG-PET/CT even for tumor size <10 mm.

Cancer incidence and mortality in Hong Kong 1983–2007. Hong Kong Cancer Registry, Hong Kong. Available: http://www3.ha.org.hk/cancereg/e_stat.asp. Accessed 2 February 2010.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;292:2632–42.

Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150:133–9.PubMedCrossRef

Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–31.PubMed

Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentaloma identified by FDG-PET. Surgery. 2001;130:941–6.PubMedCrossRef

Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid FDG-PET incidentalomas. J Clin Endocrinol Metab. 2002;87:1517–20.PubMedCrossRef

Davis PW, Perrier ND, Adler L, et al. Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation. Ann Surg. 2001;87:582–4.

McDougall IR, Davidson J, Segall GM. Positron emission tomography of thyroid, with an emphasis on thyroid cancer. Nucl Med Commun. 2001;22:485–92.PubMedCrossRef

Kim TY, Kim WB, Ryu JS, et al. 18f-fluoro-deoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope. 2005;115:1074–8.PubMedCrossRef

10.

Antoch G, Saoudi N, Kuehi H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.PubMedCrossRef

11.

Pace L, Nicola E, Klain M, et al. Diagnostic value of FDG PET/CT imaging. Q J Nucl Med Mol Imaging. 2009;53(5):503–12.PubMed

12.

Fletcher JW, Djulbegovic B, Soares H, et al. Recommendations on the use of F18-FDG PET in oncology. J Nucl Med. 2008;49:480–508.PubMedCrossRef

13.

Nakamoto Y, Tatsumi M, Hammoud D, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005;234(3):879–85.PubMedCrossRef

14.

Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated ¹⁸F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med. 2006;47:609–15.PubMed

15.

Wang W, Larson SM, Fazzari M, et al. Prognostic value of F18-FDG PET scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85(3):1107–13.PubMedCrossRef

16.

Bae JS, Chae BJ, Park CW, et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol. 2009;7:63–9.

17.

Kang WK, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by ¹⁸F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003;88(9):4100–4.PubMedCrossRef

18.

Mitchell JC, Grant F, Evenson AR, et al. Preoperative evaluation of thyroid nodules with ¹⁸F-FDG PET/CT. Surgery. 2005;138:1166–74.PubMedCrossRef

19.

Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505.PubMedCrossRef

20.

Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, Shaha AR. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol. 2007;14(11):3210–15.PubMedCrossRef

21.

Rivera M, Ghossein RA, Schoder H, et al. Histological characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113(1):48–56.PubMedCrossRef

22.

Ricarte-Filho JC, Ryder M, Chitale DA et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885–93.PubMedCrossRef

23.

Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study. Radiology. 2008;247(3):762–70.PubMedCrossRef

24.

Lang BH, CY Lo, Chan WF, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245(3):366–78.PubMedCrossRef

25.

Mitchell J, Parangi S. The thyroid incidentalomas: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR. 2005;26:37–46.PubMedCrossRef

26.

Grodski S, Delbridge L. An update on papillary microcarcinoma. Curr Opin Oncol. 2009;21(1):1–4.PubMedCrossRef

27.

Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34(1):28–35.PubMedCrossRef

28.

Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010 Jan 12 [Epub ahead of print].

29.

Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid- prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31–40.PubMedCrossRef

30.

Lo CY, Chan WF, Lang BH, et al. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg. 2006;30(5):759–66.PubMedCrossRef

31.

Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.PubMedCrossRef

32.

Kim JM, Ryu JS, Kim TY, et al. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab. 2007;92(5):1630–4.PubMedCrossRef

33.

Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91(9):3603–10.PubMedCrossRef

34.

Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3511–6.PubMedCrossRef

35.

Shattuck TM, Westra WH, Ladenson PW, et al. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Eng J Med. 2005;352:2406–12.CrossRef

36.

Robbins KT, Shaha AR, Medina JE et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134:536–8.PubMedCrossRef

37.

Lang B, Lo CY, Chan WF, Lam KY, Wan KY. Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. Ann Surg Oncol. 2007;14:1551–9.PubMedCrossRef

38.

AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, Inc.; 2002.

Title: Incidental Thyroid Carcinoma by FDG-PET/CT: A Study of Clinicopathological Characteristics
Authors: T. T. Law, MBBS, MRCS
Brian Hung-Hin Lang, MS, FRACS
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1287-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Incidental Thyroid Carcinoma by FDG-PET/CT: A Study of Clinicopathological Characteristics

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers

mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway

How Closely Should We Follow Gastric Cancer Patients Following Surgical Resection?

Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma

Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial

Impact of Circumferential Resection Margin Distance on Locoregional Recurrence and Survival after Chemoradiotherapy in Esophageal Squamous Cell Carcinoma